Loading…
Medicare and Medicaid Improvements and Adjustments Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Medicare and Medicaid Improvements and Adjustments Act of 2015 This bill amends titles XVIII (Medicare) and XIX (Medicaid) of the Social Security Act to modify payment rules and other provisions related to the Medicare and Medicaid programs. The bill includes off-campus outpatient department (OPD) services in Medicare's prospective payment system (in which predetermined amounts form the basis of payment) with respect to departments that are under development. The existing Medicare payment adjustment for cancer hospitals shall apply to off-campus OPDs. The bill temporarily prohibits specified Medicare payment adjustments related to competitive acquisition programs for certain wheelchair accessories. In addition, the bill modifies provisions related to: (1) reimbursement under Medicare for certain drugs furnished through durable medical equipment (DME), (2) Medicare payment rules for certain radiation therapy services, and (3) the treatment of Medicaid supplemental needs trusts. The bill expands criminal penalties and civil monetary penalties for certain acts involving federal health care programs. With respect to negative Medicare payment adjustments for physicians and hospitals that fail to comply with certain requirements related to electronic health records (EHR), the bill authorizes a temporary blanket exception. A patient encounter occurring at an ambulatory surgical center shall not be used to determine whether an eligible professional qualifies as a meaningful EHR user. This prohibition applies until a specified period has passed following a determination by the Department of Health and Human Services that certified EHR technology is applicable to that setting. Current law limits state reimbursement for DME under Medicaid to Medicare payment rates beginning January 1, 2019. The bill accelerates this limitation such that it begins October 1, 2018.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (8)
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2016 · fourth_quarter · Medicare/Medicaid
HR 605/S 275 - The Medicare Home Infusion Site of Care Act - Lobbied in support of passage of the legislation to ensure Medicare beneficiaries have access to home infusion. IVIG Coverage Demonstration - Worked with CMS to ensure the IVIG Demonstration is carried out in a manner that is beneficial to Medicare beneficiaries. Medicare Audits and ALJ Hearings - Continued efforts supporting reforms to the Medicare Audits system. Competitive bidding of DMEPOS - worked to ensure competitive bidding does not adversely affect the home infusion industry's ability to provide infusion services. HR 6 / HR 2581 / HR 2570 / S 2409 / HR 4273 / HR 34 - lobbied House and Senate against ASP infusion drug pricing without inclusion of a services payment for home infusion pharmacies under the Medicare DME Program. Lobbied for inclusion of services payment under the legislation. Medicare Program; Part B Drug Payment Model - lobbied House and Senate regarding the effects of the Medicare Program; Part B Drug Payment Model demonstration project released on Friday, March 11, 2016 (81 FR 13229). MLN Learning Matters SE- 1609 and DME MAC Billing Guidance-Billing for External Infusion Pumps and Drugs When Treatment Was Initiated Somewhere Other Than the Beneficiary Home - Lobbied for delay in MLN Learning Matters and a moratorium on the Billing Guidance.
Client expense: $125,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · fourth_quarter · Medicare/Medicaid
General Medicare payment policy; Centers for Medicare and Medicaid Innovation (CMMI)-related initiatives; accountable care organizations; bundled payments and payment changes to HOPD services included within H.R.4273/S.2409, Medicare & Medicaid Improvement & Adjustment Act of 2015; hospital quality measurement, H.R.2366 Field EMS Modernization & Innovation Act, and H.R.5273 Helping Hospitals Improve Patient Care Act of 2016; H.R.6 21st Century Cures Act.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS)
2016 · third_quarter · Medicare/Medicaid
HR 605/S 275 - The Medicare Home Infusion Site of Care Act - Lobbied in support of passage of the legislation to ensure Medicare beneficiaries have access to home infusion. IVIG Coverage Demonstration - Worked with CMS to ensure the IVIG Demonstration is carried out in a manner that is beneficial to Medicare beneficiaries. Medicare Audits and ALJ Hearings - Continued efforts supporting reforms to the Medicare Audits system. Competitive bidding of DMEPOS - worked to ensure competitive bidding does not adversely affect the home infusion industry's ability to provide infusion services. HR 6 / HR 2581 / HR 2570 / S 2409 / HR 4273 - lobbied House and Senate against ASP infusion drug pricing without inclusion of a services payment for home infusion pharmacies under the Medicare DME Program. Medicare Program; Part B Drug Payment Model - lobbied House and Senate regarding the effects of the Medicare Program; Part B Drug Payment Model demonstration project released on Friday, March 11, 2016 (81 FR 13229). MLN Learning Matters SE- 1609 and DME MAC Billing Guidance-Billing for External Infusion Pumps and Drugs When Treatment Was Initiated Somewhere Other Than the Beneficiary Home - Lobbied for delay in MLN Learning Matters and a moratorium on the Billing Guidance.
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Medicare/Medicaid
H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, generally H.R.5273, Helping Hospitals Improve Patient Care Act of 2016, generally
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
H.R.6, 21st Century Cures Act Biomedical innovation legislation (Senate draft) Monitor the following: H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues H.R.5273, Helping Hospitals Improve Patient Care Act of 2016 H.R.2646, Helping Families in Mental Health Crisis Act of 2015 S.2680, Mental Health Reform Act of 2016 Public Law 114-198, Comprehensive Addiction and Recovery Act of 2016
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
H.R.5926/S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2017, Medical Center related initiatives Medical Center related initiatives Biomedical innovation legislation (Senate draft) H.R.6, 21st Century Cures Act Cancer Moonshot Initiative Monitor the following: H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues Concussion issues, generally S.2624, National Biomedical Research Act S.320, Medical Innovation Act of 2015 S.2646, Helping Families in Mental Health Crisis Act of 2015 S.2680, Mental Health Reform Act of 2016 Public Law 114-198, Comprehensive Addiction and Recovery Act of 2016 H.R.5273, Helping Hospitals Improve Patient Care Act of 2016
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Cancer and medical research issues H.R.6, 21st Century Cures Act Biomedical innovation legislation (Senate draft) Big data issues H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues Cancer Moonshot Initiative Precision Medicine Initiative S.2624, National Biomedical Research Act S.320, Medical Innovation Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
H.R.2895, Medicare Patient Access to Cancer Treatment Act of 2015, generally H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues H.R.5273, Helping Hospitals Improve Patient Care Act of 2016, generally
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Medicare/Medicaid
General Medicare payment policy; Centers for Medicare and Medicaid Innovation (CMMI)-related initiatives; accountable care organizations; bundled payments and payment changes to HOPD services included within H.R.4273/S.2409, Medicare & Medicaid Improvement & Adjustment Act of 2015; hospital quality measurement, H.R.2366 Field EMS Modernization & Innovation Act, and H.R.5273 Helping Hospitals Improve Patient Care Act of 2016.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS)
2016 · second_quarter · Medicare/Medicaid
HR 605/S 275 - The Medicare Home Infusion Site of Care Act - Lobbied in support of passage of the legislation to ensure Medicare beneficiaries have access to home infusion. IVIG Coverage Demonstration - Worked with CMS to ensure the IVIG Demonstration is carried out in a manner that is beneficial to Medicare beneficiaries. Medicare Audits and ALJ Hearings - Continued efforts supporting reforms to the Medicare Audits system. Competitive bidding of DMEPOS - worked to ensure competitive bidding does not adversely affect the home infusion industry's ability to provide infusion services. HR 6 / HR 2581 / HR 2570 / S 2409 / HR 4273 - lobbied House and Senate against ASP infusion drug pricing without inclusion of a services payment for home infusion pharmacies under the Medicare DME Program. Medicare Program; Part B Drug Payment Model - lobbied House and Senate regarding the effects of the Medicare Program; Part B Drug Payment Model demonstration project released on Friday, March 11, 2016 (81 FR 13229). MLN Learning Matters SE- 1609 and DME MAC Billing Guidance-Billing for External Infusion Pumps and Drugs When Treatment Was Initiated Somewhere Other Than the Beneficiary Home - Lobbied for delay in MLN Learning Matters and a moratorium on the Billing Guidance.
Client expense: $160,000 · Firm income: Not reported
2016 · second_quarter · Health Issues
H.R.6, 21st Century Cures Act, generally Monitor the following: H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally Public Law No. 114-113, Consolidated Appropriations Act, FY2016, Medicare reimbursement H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 1622, The FDA Device Accountability Act of 2015 S. 2014, Next Generation Researchers Act S. 800, The Enhancing the Stature and Visibility of Medical Rehabilitation Research at NIH Act S. 849, Advancing Research for Neurological Diseases Act of 2015 S. 2503, Preventing Superbugs and Protecting Patients Act S. 2511, Improving Health Information Technology S. 1878, The Advancing Hope Act of 2015 S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S. 1101, The Medical Electronic Data Technology Enhancement for Consumers Health Act S. 2055, The Medical Countermeasures Innovation Act of 2015 S. 1767, The Combination Products Innovation Act of 2015 S. 1597, Patient Focused Impact Assessment Act of 2015 S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 185, Promise for Antibiotics and Therapeutics for Health Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act H.R.5273, Helping Hospitals Improve Patient Care Act of 2016 H.R.2646, Helping Families in Mental Health Crisis Act of 2015 S.2680, Mental Health Reform Act of 2016 S.524, Comprehensive Addiction and Recovery Act of 2016
2016 · second_quarter · Health Issues
S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2017, Medical Center related initiatives H.R.6, 21st Century Cures Act, Medical Center related initiatives Monitor the following: H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues Concussion issues, generally S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 1622, The FDA Device Accountability Act of 2015 S. 2014, Next Generation Researchers Act S. 800, The Enhancing the Stature and Visibility of Medical Rehabilitation Research at NIH Act S. 849, Advancing Research for Neurological Diseases Act of 2015 S. 2503, Preventing Superbugs and Protecting Patients Act S. 2511, Improving Health Information Technology S. 1878, The Advancing Hope Act of 2015 S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S. 1101, The Medical Electronic Data Technology Enhancement for Consumers Health Act S. 2055, The Medical Countermeasures Innovation Act of 2015 S. 1767, The Combination Products Innovation Act of 2015 S. 1597, Patient Focused Impact Assessment Act of 2015 S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 185, Promise for Antibiotics and Therapeutics for Health Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act S.2624, National Biomedical Research Act S.320, Medical Innovation Act of 2015 S.2646, Helping Families in Mental Health Crisis Act of 2015 S.2680, Mental Health Reform Act of 2016 S.524, Comprehensive Addiction and Recovery Act of 2016 H.R.5273, Helping Hospitals Improve Patient Care Act of 2016
2016 · second_quarter · Health Issues
Cancer research issues H.R.6, 21st Century Cures Act, Medical research issues Big data issues H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues Cancer Moonshot Initiative Precision Medicine S.2624, National Biomedical Research Act S.320, Medical Innovation Act of 2015 S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 1622, The FDA Device Accountability Act of 2015 S. 2014, Next Generation Researchers Act S. 800, The Enhancing the Stature and Visibility of Medical Rehabilitation Research at NIH Act S. 849, Advancing Research for Neurological Diseases Act of 2015 S. 2503, Preventing Superbugs and Protecting Patients Act S. 2511, Improving Health Information Technology S. 1878, The Advancing Hope Act of 2015 S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S. 1101, The Medical Electronic Data Technology Enhancement for Consumers Health Act S. 2055, The Medical Countermeasures Innovation Act of 2015 S. 1767, The Combination Products Innovation Act of 2015 S. 1597, Patient Focused Impact Assessment Act of 2015 S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 185, Promise for Antibiotics and Therapeutics for Health Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act
Client expense: Not reported · Firm income: $30,000
2016 · second_quarter · Medicare/Medicaid
Monitor the following: H.R.2895, Medicare Patient Access to Cancer Treatment Act of 2015, generally H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues H.R.5273, Helping Hospitals Improve Patient Care Act of 2016, generally
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Medicare/Medicaid
General Medicare payment policy; Centers for Medicare and Medicaid Innovation (CMMI)-related initiatives; accountable care organizations; bundled payments and payment changes to HOPD services included within H.R.4273/S.2409, Medicare & Medicaid Improvement & Adjustment Act of 2015; hospital quality measurement, H.R.2366 Field EMS Modernization & Innovation Act, and H.R.5273 Helping Hospitals Improve Patient Care Act of 2016.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS)
2016 · first_quarter · Medicare/Medicaid
Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 8, 2016) - Provisions related to the Medicare Part B Drug Payment Model Medicaid Program: Covered Outpatient Drugs (CMS-2345-FC) - Provisions related to line extension drug definition, effective date and other issues S. 31: Medicare Prescription Drug Price Negotiation Act of 2015 - Provisions related to Secretary negotiation authority in Part D program S. 141: Protecting Seniors' Access to Medicare Act of 2015 - Provisions related to Independent Payment Advisory Board (IPAB) repeal S. 275: Medicare Home Infusion Site of Care Act of 2015 - Provisions related to Medicare coverage S. 480: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 - Provisions related to the reauthorization of the national controlled substance monitoring program S. 648: Medicare Formulary Improvement Act of 2015 - Provisions related to codification of six protected classes in Part D program S. 1083: Medicare Drug Savings Act of 2015 - Provisions related to drug rebates in Medicare Part D S. 1253: Patient Access to Disposable Medical Technology Act of 2015 - Provisions related to capitated payments for disposable medical technology S. 1396: Value-Based Insurance Design Seniors Copayment Reduction Act of 2015 - Provisions related to changes to the Medicare Advantage Program S. 1884: Medicare Prescription Drug Savings and Choice Act of 2015 - Provisions related to the Medicare Operated Prescription Drug Plan Option S. 1913: Stopping Medication Abuse and Protecting Seniors Act of 2015 - Provisions related to programs to prevent prescription drug abuse under the Medicare program S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to Secretary negotiation authority in Part D program, Medicare and Medicaid rebates, resolution of government enforcement actions, and reporting of certain drug manufacturer expenditures S. 2409: Medicare and Medicaid Improvements and Adjustments Act of 2015 - Provisions related to outpatient reimbursement rates S. 2646: Veterans Choice Improvement Act of 2016 - Provisions related to TRICARE drug pricing H.R. 22: FAST Act - Medicare related offsets to the biopharmaceutical industry HR. 512 - the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 H.R. 1190: Protecting Seniors Access to Medicare Act of 2015 - Provisions related to IPAB repeal H.R. 2005: Medicare Drug Savings Act of 2015 - Provisions related to changes to Part D rebates H.R. 2298: Medicare Patient Safety and Drug Abuse Prevention Act - Provisions related to the design of a Part D Lock-in program H.R. 3513: Prescription Drug Affordability Act of 2015 - Provisions related to Secretary negotiation authority in Part D program, Medicare and Medicaid rebates, resolution of government enforcement actions, and reporting of certain drug manufacturer expenditures H.R. 4273: Medicare and Medicaid Improvements and Adjustments Act of 2015 - Provisions related to outpatient reimbursement rates Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies, and Revisions Related to Third Party Liability; Proposed rules [CMS-2390-P] - Provisions related to Medicaid Proposed Medicare hospital outpatient prospective payment system (OPPS) rule for 2016 (CMS-1633-P) Proposed Medicare physician fee schedule (MPFS) rule for 2016 (CMS-1631-P) Hospital Improvements for Payment Act (discussion draft) - Provisions related to Medicare Parts A and B reform Department of Health and Human Services (HHS) delivery system reform issues and regulatory barriers to innovation Medicare Part B Average Sales Price (ASP) policy issues Medicare Part D rebates policy issues Drug cost and pricing policy issues Transparency policy issues Medication adherence policy issues Alternative payment models policy issues Value-based arrangements policy issues Coding and reimbursement policy issues including for biologics Center for Medicare and Medicaid Innovation (CMMI) transparency policy issues Chronic Care Working Group - Medicare policy affecting drugs
2016 · first_quarter · Medicare/Medicaid
Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 8, 2016) - Provisions related to the Medicare Part B Drug Payment Model Medicaid Program: Covered Outpatient Drugs (CMS-2345-FC) - Provisions related to line extension drug definition, effective date and other issues S. 31: Medicare Prescription Drug Price Negotiation Act of 2015 - Provisions related to Secretary negotiation authority in Part D program S. 141: Protecting Seniors' Access to Medicare Act of 2015 - Provisions related to Independent Payment Advisory Board (IPAB) repeal S. 275: Medicare Home Infusion Site of Care Act of 2015 - Provisions related to Medicare coverage S. 480: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 - Provisions related to the reauthorization of the national controlled substance monitoring program S. 648: Medicare Formulary Improvement Act of 2015 - Provisions related to codification of six protected classes in Part D program S. 1083: Medicare Drug Savings Act of 2015 - Provisions related to drug rebates in Medicare Part D S. 1253: Patient Access to Disposable Medical Technology Act of 2015 - Provisions related to capitated payments for disposable medical technology S. 1396: Value-Based Insurance Design Seniors Copayment Reduction Act of 2015 - Provisions related to changes to the Medicare Advantage Program S. 1884: Medicare Prescription Drug Savings and Choice Act of 2015 - Provisions related to the Medicare Operated Prescription Drug Plan Option S. 1913: Stopping Medication Abuse and Protecting Seniors Act of 2015 - Provisions related to programs to prevent prescription drug abuse under the Medicare program S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to Secretary negotiation authority in Part D program, Medicare and Medicaid rebates, resolution of government enforcement actions, and reporting of certain drug manufacturer expenditures S. 2409: Medicare and Medicaid Improvements and Adjustments Act of 2015 - Provisions related to outpatient reimbursement rates S. 2646: Veterans Choice Improvement Act of 2016 - Provisions related to TRICARE drug pricing H.R. 22: FAST Act - Medicare related offsets to the biopharmaceutical industry H.R. 1190: Protecting Seniors Access to Medicare Act of 2015 - Provisions related to IPAB repeal H.R. 2005: Medicare Drug Savings Act of 2015 - Provisions related to changes to Part D rebates H.R. 2298: Medicare Patient Safety and Drug Abuse Prevention Act - Provisions related to the design of a Part D Lock-in program H.R. 3513: Prescription Drug Affordability Act of 2015 - Provisions related to Secretary negotiation authority in Part D program, Medicare and Medicaid rebates, resolution of government enforcement actions, and reporting of certain drug manufacturer expenditures H.R. 4273: Medicare and Medicaid Improvements and Adjustments Act of 2015 - Provisions related to outpatient reimbursement rates Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies, and Revisions Related to Third Party Liability; Proposed rules [CMS-2390-P] - Provisions related to Medicaid Proposed Medicare hospital outpatient prospective payment system (OPPS) rule for 2016 (CMS-1633-P) Proposed Medicare physician fee schedule (MPFS) rule for 2016 (CMS-1631-P) Hospital Improvements for Payment Act (discussion draft) - Provisions related to Medicare Parts A and B reform Department of Health and Human Services (HHS) delivery system reform issues and regulatory barriers to innovation Medicare Part B Average Sales Price (ASP) policy issues Medicare Part D rebates policy issues Drug cost and pricing policy issues Transparency policy issues Medication adherence policy issues Alternative payment models policy issues Value-based arrangements policy issues Coding and reimbursement policy issues including for biologics Center for Medicare and Medicaid Innovation (CMMI) transparency policy issues Chronic Care Working Group - Medicare policy affecting drugs
2016 · first_quarter · Medicare/Medicaid
Policies related to graduate medical education and payment for primary care including S. 737, Ensuring Access to Primary Care for Women & Children Act; general education around primary care issues including Congressional Primary Care Caucus; implementation of physician payment policy within H.R. 2, the Medicare Access and CHIP Reauthorization Act; and issues related to the meaningful use electronic health record program including S. 2425, the Patient Access and Medicare Protection Act, H.R. 3940 Meaningful Use Hardship Relief Act of 2015, H.R. 4273/S. 2409 Medicare and Medicaid Improvements and Adjustments Act of 2015 and H.R. 2029, Consolidated Appropriations Act of 2016; policies related to addressing mental health; and policies related to opioid abuse.
Client expense: Not reported · Firm income: $60,000
2016 · first_quarter · Medicare/Medicaid
Policies affecting hospitals in the Affordable Care Act (P.L. 111-148 and P.L. 111-152; H.R. 2513, The Promoting Access, Competition, and Equity Act of 2015; HR. 976, the Patient Access to Higher Quality Health Care Act; H.R. 4273/S.2409, Medicare and Medicaid Improvement and Adjustments Act 2015.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Medicare/Medicaid
Policies related to graduate medical education and payment for primary care including S. 737, Ensuring Access to Primary Care for Women & Children Act; general education around primary care issues including Congressional Primary Care Caucus; implementation of physician payment policy within H.R. 2, the Medicare Access and CHIP Reauthorization Act; and issues related to the meaningful use electronic health record program including S. 2425, the Patient Access and Medicare Protection Act, H.R. 3940 Meaningful Use Hardship Relief Act of 2015, H.R. 4273/S. 2409 Medicare and Medicaid Improvements and Adjustments Act of 2015 and H.R. 2029, Consolidated Appropriations Act of 2016; policies related to addressing mental health; and policies related to opioid abuse.
Client expense: Not reported · Firm income: $60,000
2016 · first_quarter · Medicare/Medicaid
HR 605/S 275 - The Medicare Home Infusion Site of Care Act - Lobbied in support of passage of the legislation to ensure Medicare beneficiaries have access to home infusion. IVIG Coverage Demonstration - Worked with CMS to ensure the IVIG Demonstration is carried out in a manner that is beneficial to Medicare beneficiaries. Medicare Audits and ALJ Hearings - Continued efforts supporting reforms to the Medicare Audits system. Competitive bidding of DMEPOS - worked to ensure competitive bidding does not adversely affect the home infusion industry's ability to provide infusion services. HR 6 / HR 2581 / HR 2570 / S 2409 / HR 4273 - lobbied House and Senate against ASP infusion drug pricing without inclusion of a services payment for home infusion pharmacies under the Medicare DME Program. Medicare Program; Part B Drug Payment Model - lobbied House and Senate regarding the effects of the Medicare Program; Part B Drug Payment Model demonstration project released on Friday, March 11, 2016 (81 FR 13229).
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · first_quarter · Medicare/Medicaid
Public Law 114-10, Medicare Access and CHIP Reauthorization Act of 2015, Medicare reimbursement issues Monitor the following: H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
H.R.6, 21st Century Cures Act, generally Monitor the following: H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally Public Law No. 114-113, Consolidated Appropriations Act, FY2016, Medicare reimbursement H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 1622, The FDA Device Accountability Act of 2015 S. 2014, Next Generation Researchers Act S. 800, The Enhancing the Stature and Visibility of Medical Rehabilitation Research at NIH Act S. 849, Advancing Research for Neurological Diseases Act of 2015 S. 2503, Preventing Superbugs and Protecting Patients Act S. 2511, Improving Health Information Technology S. 1878, The Advancing Hope Act of 2015 S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S. 1101, The Medical Electronic Data Technology Enhancement for Consumers Health Act S. 2055, The Medical Countermeasures Innovation Act of 2015 S. 1767, The Combination Products Innovation Act of 2015 S. 1597, Patient Focused Impact Assessment Act of 2015 S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 185, Promise for Antibiotics and Therapeutics for Health Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act
Client expense: Not reported · Firm income: $30,000
2016 · first_quarter · Health Issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2017, Medical Center related initiatives H.R.6, 21st Century Cures Act, Medical Center related initiatives Monitor the following: H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues Concussion issues, generally S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 1622, The FDA Device Accountability Act of 2015 S. 2014, Next Generation Researchers Act S. 800, The Enhancing the Stature and Visibility of Medical Rehabilitation Research at NIH Act S. 849, Advancing Research for Neurological Diseases Act of 2015 S. 2503, Preventing Superbugs and Protecting Patients Act S. 2511, Improving Health Information Technology S. 1878, The Advancing Hope Act of 2015 S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S. 1101, The Medical Electronic Data Technology Enhancement for Consumers Health Act S. 2055, The Medical Countermeasures Innovation Act of 2015 S. 1767, The Combination Products Innovation Act of 2015 S. 1597, Patient Focused Impact Assessment Act of 2015 S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 185, Promise for Antibiotics and Therapeutics for Health Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act S.2624, National Biomedical Research Act S.320, Medical Innovation Act of 2015
2016 · first_quarter · Health Issues
Cancer research issues H.R.6, 21st Century Cures Act, Medical research issues Big data issues H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues Cancer Moonshot Initiative Precision Medicine S.2624, National Biomedical Research Act S.320, Medical Innovation Act of 2015 S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 1622, The FDA Device Accountability Act of 2015 S. 2014, Next Generation Researchers Act S. 800, The Enhancing the Stature and Visibility of Medical Rehabilitation Research at NIH Act S. 849, Advancing Research for Neurological Diseases Act of 2015 S. 2503, Preventing Superbugs and Protecting Patients Act S. 2511, Improving Health Information Technology S. 1878, The Advancing Hope Act of 2015 S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S. 1101, The Medical Electronic Data Technology Enhancement for Consumers Health Act S. 2055, The Medical Countermeasures Innovation Act of 2015 S. 1767, The Combination Products Innovation Act of 2015 S. 1597, Patient Focused Impact Assessment Act of 2015 S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 185, Promise for Antibiotics and Therapeutics for Health Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act
Client expense: Not reported · Firm income: $30,000
2016 · first_quarter · Medicare/Medicaid
Monitor the following: H.R.2895, Medicare Patient Access to Cancer Treatment Act of 2015, generally H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE
2016 · first_quarter · Medicare/Medicaid
General Medicare payment policy; Centers for Medicare and Medicaid Innovation (CMMI)-related initiatives; accountable care organizations; bundled payments and payment changes to HOPD services included within H.R.4273/S.2409, Medicare & Medicaid Improvement & Adjustment Act of 2015; hospital quality measurement.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS)
2015 · fourth_quarter · Medicare/Medicaid
P.L. 114-74, Bipartisan Budget Act of 2015, Issues pertaining to the implication of site neutral payments for hospital outpatient department services. H.R. 4273, S. 2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Issues pertaining to improving payments for hospital outpatient department services. P.L. 114-113, Consolidated Appropriations Act of 2016, Issues and language pertaining to site neutral payments for hospital outpatient departments. H.R. 2124, S. 1148, Resident Physician Shortage Reduction Act of 2015, Issues pertaining to increasing the cap on the number of resident physicians. Issues pertaining to protecting funding for direct graduate medical education and indirect medical education. Issues pertaining to the 340B drug pricing program. H.R. 1343, S. 688, Establishing Beneficiary Equity in the Hospital Readmission Program Act of 2015, Issues pertaining to adjustment for socioeconomic status in the hospital re-admissions program.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medicare/Medicaid
Policies related to graduate medical education and payment for primary care including S. 737, Ensuring Access to Primary Care for Women & Children Act; general education around primary care issues including congressional primary caucus; implementation of physician payment policy within H.R. 2, the Medicare Access and CHIP Reauthorization Act; and issues related to the meaningful use electronic health record program including S. 2425, the Patient Access and Medicare Protection Act, H.R. 3940 Meaningful Use Hardship Relief Act of 2015, H.R. 4273/S. 2409 Medicare and Medicaid Improvements and Adjustments Act of 2015 and H.R. 2029, Consolidated Appropriations Act of 2016.
Client expense: Not reported · Firm income: $60,000
2015 · fourth_quarter · Medicare/Medicaid
General Medicare payment policy; Centers for Medicare and Medicaid Innovation (CMMI)-related initiatives; accountable care organizations; bundled payments and payment changes to HOPD services included within H.R.4273/S.2409, Medicare & Medicaid Improvement & Adjustment Act of 2015.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS)
2015 · fourth_quarter · Medicare/Medicaid
P.L. 114-74, Bipartisan Budget Act of 2015, Issues pertaining to the implication of site neutral payments for hospital outpatient department services. H.R. 4273, S. 2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Issues pertaining to improving payments for hospital outpatient department services. P.L. 114-113, Consolidated Appropriations Act, 2016, Issues and language pertaining to site neutral payments for hospital outpatient departments. H.R. 2124, S. 1148, Resident Physician Shortage Reduction Act of 2015, Issues pertaining to increasing the cap on the number of resident physicians. Issues pertaining to protecting funding for direct graduate medical education and indirect medical education. Issues pertaining to the 340B drug pricing program. H.R. 1343, S. 688, Establishing Beneficiary Equity in the Hospital Readmission Program Act of 2015, Issues pertaining to adjustment for socioeconomic status in the hospital readmissions program.
Client expense: Not reported · Firm income: $70,000
2015 · fourth_quarter · Medicare/Medicaid
Policies affecting hospitals in the Affordable Care Act (P.L. 111-148 and P.L. 111-152) and H.R.2029, Consolidated Appropriations Act; H.R. 2513, The Promoting Access, Competition, and Equity Act of 2015; HR. 976, the Patient Access to Higher Quality Health Care Act; H.R. 4273/S.2409, Medicare and Medicaid Improvement and Adjustments Act 2015.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medicare/Medicaid
S. 31: Medicare Prescription Drug Price Negotiation Act of 2015 - Provisions related to Secretary negotiation authority in Part D program S. 141: Protecting Seniors' Access to Medicare Act of 2015 - Provisions related to Independent Payment Advisory Board (IPAB) repeal S. 275: Medicare Home Infusion Site of Care Act of 2015 - Provisions related to Medicare coverage S. 480: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 - Provisions related to the reauthorization of the national controlled substance monitoring program S. 648: Medicare Formulary Improvement Act - Provisions related to codification of six protected classes in Part D program S. 1083: Medicare Drug Savings Act of 2015 - Provisions related to drug rebates in Medicare Part D S. 1253: Patient Access to Disposable Medical Technology Act of 2015 - Provisions related to capitated payments for disposable medical technology S. 1396: Value-Based Insurance Design Seniors Copayment Reduction Act of 2015 - Provisions related to changes to the Medicare Advantage Program S. 1884: Medicare Prescription Drug Savings and Choice Act of 2015 - Provisions related to the Medicare Operated Prescription Drug Plan Option S. 1913: Stopping Medication Abuse and Protecting Seniors Act of 2015 - Provisions related to programs to prevent prescription drug abuse under the Medicare program S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to Secretary negotiation authority in Part D program, Medicare and Medicaid rebates, resolution of government enforcement actions, and reporting of certain drug manufacturer expenditures S. 2409: Medicare and Medicaid Improvements and Adjustments Act of 2015 - Provisions related to outpatient reimbursement rates H.R. 22: FAST Act - Medicare related offsets to the biopharmaceutical industry H.R. 1190: Protecting Seniors Access to Medicare Act of 2015 - Provisions related to IPAB repeal H.R. 2005: Medicare Drug Savings Act of 2015 - Provisions related to changes to Part D rebates H.R. 2298: Medicare Patient Safety and Drug Abuse Prevention Act - Provisions related to the design of a Part D Lock-in program H.R. 3513: Prescription Drug Affordability Act of 2015 - Provisions related to Secretary negotiation authority in Part D program, Medicare and Medicaid rebates, resolution of government enforcement actions, and reporting of certain drug manufacturer expenditures H.R. 3819: Surface Transportation Extension Act of 2015 - Medicare related offsets to the biopharmaceutical industry H.R. 4273: Medicare and Medicaid Improvements and Adjustments Act of 2015 - Provisions related to outpatient reimbursement rates Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies, and Revisions Related to Third Party Liability; Proposed rules [CMS-2390-P] - Provisions related to Medicaid Medicaid Program; Covered Outpatient Drugs; Proposed rule [CMS-2345-F] - Provisions related to calculating Average Manufacturer Price (AMP) Proposed Medicare hospital outpatient prospective payment system (OPPS) rule for 2016 (CMS-1633-P) Proposed Medicare physician fee schedule (MPFS) rule for 2016 (CMS-1631-P) Hospital Improvements for Payment Act (discussion draft) - Provisions related to Medicare Parts A and B reform Department of Health and Human Services (HHS) delivery system reform issues and regulatory barriers to innovation Medicare Part B Average Sales Price (ASP) policy issues Medicare Part D rebates policy issues Drug cost and pricing policy issues Transparency policy issues Medication adherence policy issues Alternative payment models policy issues Chronic Care Working Group - Medicare policy affecting drugs
2015 · fourth_quarter · Medicare/Medicaid
HR 605/S 275 - The Medicare Home Infusion Site of Care Act - Lobbied in support of passage of the legislation to ensure Medicare beneficiaries have access to home infusion. IVIG Coverage Demonstration - Worked with CMS to ensure the IVIG Demonstration is carried out in a manner that is beneficial to Medicare beneficiaries. Medicare Audits and ALJ Hearings - Continued efforts supporting reforms to the Medicare Audits system. Competitive bidding of DMEPOS - worked to ensure competitive bidding does not adversely affect the home infusion industry's ability to provide infusion services. HR 6 / HR 2581 / HR 2570 / S 2409 / HR 4273 - lobbied House and Senate against ASP infusion drug pricing without inclusion of a services payment for home infusion pharmacies under the Medicare DME Program.
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · fourth_quarter · Health Issues
H.R.6, 21st Century Cures Act, generally Monitor the following: H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally Public Law No. 114-113, Consolidated Appropriations Act, FY2016, Medicare reimbursement H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
H.R.3020/S.1695, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2016, Medical Center related initiatives H.R.6, 21st Century Cures Act, Medical Center related initiatives Public Law No. 114-113, Consolidated Appropriations Act, FY2016, Medicare reimbursement Monitor the following: H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
Cancer research issues H.R.6, 21st Century Cures Act, Medical research issues Big data issues Public Law No. 114-113, Consolidated Appropriations Act, FY2016, Medicare reimbursement H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medicare/Medicaid
Monitor the following: H.R.2895, Medicare Patient Access to Cancer Treatment Act of 2015, generally H.R.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally H.R.3288, Strengthening DSH and Medicare Through Subsidy Recapture and Payment Reform Act of 2015, generally H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
H.R.6, 21 Century Cures Act, generally Monitor the following: H.4.3291, Medicare Crosswalk Hospital Code Development Act of 2015, generally H.R.3288, Strengthening DSH and Medicare through Subsidy Recapture and Payment Reform act of 2015, generally H.R.3292, Medicare IME Pool Act of 2015, generally Public Law No. 114-113, Consolidated Appropriations Act, FY2016, Medicare reimbursement H.R.4273/S.2409, Medicare and Medicaid Improvements and Adjustments Act of 2015, Medicare reimbursement issues
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: Not reported · Firm income: $30,000
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
Client expense: $1,490,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), Vice President of the U.S.
Client expense: $5,950,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), Vice President of the U.S.
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: Not reported · Firm income: $30,000
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $3,820,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)